

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



October 11, 2023

### MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™

Effective **October 11, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
Beyfortus™ (nirsevimab-alip) solution for subcutaneous (SC) injection
Daxxify® (daxibotulinumtoxinA-lanm) lyophilized powder for reconstitution and intramuscular (IM) injection
Elrexfio™ (elranatamab-bcmm) solution for subcutaneous (SC) injection
Izervay™ (avacincaptad pegol) solution for intravitreal (IVI) injection
Talvey™ (talquetamab-tgvs) solution for subcutaneous (SC) injection
Veopoz™ (pozelimab-bbfg) solution for intravenous (IV) or subcutaneous (SC) administration

#### Products Impacted

These exclusions apply to Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

#### Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. For all other questions, contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP85-23

Distribution: [bluecrossmn.com/providers/forms-and-publications](https://bluecrossmn.com/providers/forms-and-publications)